Breast Cancer Nutrition Product Market

How big is Breast Cancer Nutrition Product Market in 2026?

The breast cancer nutrition product market is estimated at USD 380.4 million in 2025 and is likely to reach USD 416.9 million in 2026. Sales of breast cancer nutrition products are expected to grow at a 9.6% CAGR and reach USD 1,042.7 million by 2036.

Key trends in the breast cancer nutrition product market point to oncology teams writing nutrition into treatment plans and patients refilling products at home. For 2025, sales of breast cancer nutrition products are estimated at USD 380.4 million. From that base, the breast cancer nutrition product market is forecast at USD 416.9 million in 2026 and USD 1,042.7 million by 2036, on a 9.6% CAGR. Within that, FMI analysis shows the steepest gains in protein drinks taken during chemotherapy, when appetite and taste change most. Treatment cycles repeat every few weeks, so a tolerated product becomes a standing order for months.

Recent shelf moves change the buying choice for patients. For example, Kate Farms said retail distribution of the High Protein Nutrition Shake grew over sevenfold after the Walmart launch in Q4 2025, and expected availability in over 6,800 Walmart and CVS stores by August 2026.[1] Shelf presence on that scale puts a medical shake in front of patients who never see a dietitian. The company also said products are eligible for coverage through Medicare, Medicaid and private insurance.[1] As a result, patients now weigh a self-pay shelf purchase against a covered prescription, and oncology dietitians will need to name the product and the route at each visit.

Key Market Trends & Insights

• High-protein ONS is forecast to remain the largest product type in 2026, with 48.1% of sales, against about 19.6% for symptom-adapted supplements, as oncology dietitians usually start with complete protein drinks.
• Sales during chemotherapy and targeted therapy are likely to reach 47.4% of treatment phase demand in 2026. Appetite loss is most severe during systemic treatment, and the patient pool is large. To gauge the pool, CDC counted 279,731 new breast cancer cases among US women in 2022.[2] Each new case starting chemotherapy adds weeks of daily supplement use.
• Ready-to-drink packs suit patients too tired to mix powder, and are projected to make up 44.3% of form sales in 2026.
• Within care settings, home care will hold 51% in 2026, with cancer centers near 32.6%.
• Self-pay online buying is forecast at 38.4% of access route sales in 2026. Physical retail is opening up as well. On the retail side, Kate Farms added a CVS launch to Walmart shelves for the High Protein Nutrition Shake in July 2026.[1] Drugstore listings give patients a same-day refill option beside online subscriptions.

Regional Highlights

• South Korea is projected to lead country growth at 9.9%, 0.3 points above the global CAGR, with survivorship care keeping patients buying for years.
• Demand in the United States is forecast at 9.3% on wide shelf access, and in the United Kingdom at 9% under national survival targets. France and Germany grow within 0.2 points of each other, and Japan is slowest at 7.5%.
• The Korean survivor population is large and still growing. South Korea counted 2,732,906 cancer survivors in 2023, with breast cancer the fourth most common new cancer, Dailypharm reported on 20 January 2026.[3] Survivors buying protein for weight and muscle extend demand well past the end of treatment.

Market Size & Forecast

Table 1: Market Size and Forecast for the Breast Cancer Nutrition Product Market (USD million and percentage), 2025 to 2036

Metric	Value
2025 Market Size	USD 380.4 million
Estimated Market Size in 2026	USD 416.9 million
Projected Market Size by 2036	USD 1,042.7 million
CAGR, 2026 to 2036	9.6%
Added Revenue, 2026 to 2036	USD 625.8 million
Market Expansion Multiple	2.5x

More breast cancer treatment now happens in outpatient clinics, which moves purchases of breast cancer nutrition products from the ward to the home. For instance, in the United States, CDC reported 279,731 new breast cancer cases among women in 2022 and put annual medical costs for breast cancer at USD 29.8 billion in 2020, the highest treatment cost of any cancer.[2] Each new patient adds months of possible supplement use. By comparison, oral supplements as a whole grow more slowly, and the oral clinical nutrition supplements market is projected at a 6.1% CAGR. By FMI estimates, longer treatment and survivorship periods add USD 625.8 million to the breast cancer nutrition product market over 2026 to 2036, bringing the 2036 figure to roughly two and a half times the 2026 base. Even so, products sold with loose cancer claims are the main risk, as care teams steer patients away from them.

Guidelines, Survival Targets and Shelf Access

Clinical bodies are bringing nutrition into cancer pathways. For example, the AWMF published a new German guideline on clinical nutrition in oncology, register number 073-006OL, on 19 February 2026, aiming to counter undernutrition across the whole course of disease and to develop quality indicators for certification.[4] Quality indicators tied to certification will push German cancer centres to screen and supply nutrition routinely. In England, the National Cancer Plan set an ambition for 75% of people diagnosed with cancer to survive five years or more by 2035, Cancer Research UK reported on 4 February 2026.[5] In turn, longer survival extends the period in which patients buy nutrition products.

Shelf and coverage access is widening at the same time. To illustrate, Kate Farms is in over 1,500 hospitals and medical settings, and the High Protein Nutrition Shake was due in over 6,800 Walmart and CVS stores by August 2026.[1] A brand present in both hospitals and mass retail keeps patients on the same shake after discharge. Behind that brand, Danone combined Kate Farms with Nutricia, Real Food Blends and Functional Formularies in July 2025 to serve hospitals, home, online and retail.[6] As a result, patients leaving a cancer center can now find the same brand at a pharmacy or online.

Table 2: Guideline, Survival and Access Indicators for the Breast Cancer Nutrition Product Market (cases, targets and stores), 2022 to 2026

Indicator	Data Point	Relevance	Source
CDC breast cancer data, May 2026	279,731 new female cases in 2022	Size of the treated patient pool in the United States	[2]
AWMF oncology nutrition guideline, February 2026	Register 073-006OL; valid to January 2031	Structured nutrition care in Germany	[4]
National Cancer Plan for England, February 2026	75% five-year survival ambition by 2035	Longer survivorship nutrition use	[5]
Korean cancer registry, January 2026	2,732,906 survivors; breast cancer 94.7% five-year survival	Survivor base in South Korea	[3]
Kate Farms retail expansion, July 2026	Over 6,800 Walmart and CVS stores by August 2026	Self-pay shelf access	[1]
Nestlé Health Science, 2025	3.2% organic growth	Supplier momentum in medical nutrition	[7]

Analyst Perspective

“Breast cancer nutrition is bought one treatment cycle at a time, and the product a patient tolerates in the first cycle usually stays for the remaining cycles. I see taste change as the main reason patients switch, so flavour range and clear shelf access matter as much as protein content. I expect home refills of tolerated drinks to keep growing, opening a quieter reorder channel outside the clinic.”

- Anurag Sharma, Principal Consultant, Future Market Insights.

How is the breast cancer nutrition product market segmented?

The market is segmented into product type, treatment phase, product form, care setting, access route, and region. High-protein ONS is expected to lead product type with 48.1% share in 2026, and chemotherapy and targeted therapy lead treatment phase with 47.4%.

By product type: high-protein ONS, symptom-adapted supplements, fortified meals and snacks, protein modules, and others.

By treatment phase: chemotherapy and targeted therapy, surgery and radiotherapy recovery, endocrine therapy, and survivorship.

By product form: ready-to-drink, powder, puddings and semi-solids, and others.

By care setting: home care, cancer centers, and hospital oncology wards.

By access route: self-pay online, self-pay pharmacy and retail, prescribed and reimbursed, and cancer center supply.

By region: patients in treatment and survivorship in North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Why does high-protein ONS lead breast cancer nutrition product sales by product type?

High-protein ONS is expected to lead product type sales with 48.1% share in 2026, ahead of symptom-adapted supplements at about 19.6% and fortified meals and snacks at an estimated 12.4%.

Table 3: Product Type Share for the Breast Cancer Nutrition Product Market (percentage share), 2026

Product Type	Estimated Share (2026)
High-Protein ONS	48.1%
Symptom-Adapted Supplements	19.6%
Fortified Meals and Snacks	12.4%
Protein Modules	10.7%
Others	9.2%
Total	100.0%

Table 4: Product Type Leadership and Market Growth for the Breast Cancer Nutrition Product Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	9.6%
Leading Segment	High-Protein ONS

In the product split, high-protein ONS is expected to lead in 2026 at 48.1%, as oncology dietitians reach first for a complete drink with protein and energy when patients eat less. By contrast, symptom-adapted supplements, about 19.6%, include clear, juice-style and sensory-adapted drinks for taste change and sore mouth, a smaller group of patients. Fortified meals and snacks, near 12.4%, suit patients still eating but short on protein. Protein modules at 10.7% add protein to food or drinks without a full product switch. Vitamin and bone-health products sold alongside treatment make up the remaining 9.2%. Across oncology care, growth of the oncology nutrition market spans every tumour type, and breast cancer has the highest treatment cost of any cancer in the United States, according to CDC.[2] High treatment costs make care teams keen to prevent weight loss that delays therapy. Over the forecast period, high-protein drinks will keep the lead as treatment moves to outpatient clinics.

• The leading group mixes milk-style and plant-based shakes with compact high-protein drinks.
• Plant-based shakes are entering clinical supply. Kate Farms is in over 1,500 hospitals and medical settings in the United States.[1] Hospital presence lets the brand reach patients at the first dietitian visit.

What keeps chemotherapy and targeted therapy ahead in breast cancer nutrition product sales by treatment phase?

Chemotherapy and targeted therapy are projected to lead treatment phase sales with 47.4% share in 2026, with surgery and radiotherapy recovery at about 21.8% and endocrine therapy near 17.5%.

Table 5: Treatment Phase Share for the Breast Cancer Nutrition Product Market (percentage share), 2026

Treatment Phase	Estimated Share (2026)
Chemotherapy and Targeted Therapy	47.4%
Surgery and Radiotherapy Recovery	21.8%
Endocrine Therapy	17.5%
Survivorship	13.3%
Total	100.0%

Chemotherapy and targeted therapy are projected to stay the top phase in 2026, at 47.4%, as nausea, taste change and appetite loss peak during systemic treatment. By comparison, surgery and radiotherapy recovery, about 21.8%, covers shorter periods of higher protein need around an operation or a course of radiation. Endocrine therapy, near 17.5%, runs for years, though patients on tablets buy nutrition products less often. Finally, survivorship, an estimated 13.3%, centres on weight and muscle, and buying turns occasional. The treated population remains large. On case numbers, CDC reported 42,213 breast cancer deaths among US women in 2023, alongside 279,731 new cases in 2022.[2] A caseload of that size keeps chemotherapy clinics the main source of first orders. Systemic therapy will keep the lead as more patients receive treatment in outpatient settings.

• Chemotherapy cycles, HER2-targeted drugs and newer targeted agents define the leading phase.
• Survival in Korea is high. The Korean registry reported a 94.7% five-year survival rate for breast cancer in January 2026.[3] High survival lengthens the survivorship stage and the years of protein buying.

Why do ready-to-drink packs lead breast cancer nutrition product sales by product form?

Ready-to-drink packs are likely to lead product form sales with 44.3% share in 2026, ahead of powder at about 28.2% and puddings and semi-solids at roughly 17.1%.

Table 6: Product Form Share for the Breast Cancer Nutrition Product Market (percentage share), 2026

Product Form	Estimated Share (2026)
Ready-to-Drink	44.3%
Powder	28.2%
Puddings and Semi-Solids	17.1%
Others	10.4%
Total	100.0%

Ready-to-drink packs will hold the form lead in 2026 at 44.3%, as patients on chemotherapy often feel too tired to mix or cook. On the other hand, powder, about 28.2%, costs less per serving and suits survivors adding protein to smoothies, but each serving needs preparation. Puddings and semi-solids, near 17.1%, help patients with mouth sores who find thin liquids hard. The last 10.4% goes to bars and soups. Protein powders also sell widely outside cancer care, and growth of the protein supplements market keeps generic tubs on the same pharmacy shelves. Looking ahead, bottles will keep the lead in active treatment, and powders will gain among survivors.

• The ready-to-drink group runs from plastic bottles to cartons and compact 125 ml drinks.
• Taste testing is now part of product launches. Kate Farms added a vanilla flavour to the High Protein Nutrition Shake after 611 taste tests.[1] Testing on that scale targets the taste changes that make patients drop a drink.

Why does home care lead breast cancer nutrition product sales by care setting?

Home care is estimated to lead care setting sales with 51% share in 2026, with cancer centers at about 32.6% and hospital oncology wards near 16.4%.

Table 7: Care Setting Share for the Breast Cancer Nutrition Product Market (percentage share), 2026

Care Setting	Estimated Share (2026)
Home Care	51%
Cancer Centers	32.6%
Hospital Oncology Wards	16.4%
Total	100.0%

Home care is estimated to lead settings in 2026 at 51%, as most breast cancer treatment is given in outpatient visits and patients eat and drink at home between them. Meanwhile, cancer centers, about 32.6%, supply products during infusion days and dietitian visits, though each visit covers only a few days of use. Hospital oncology wards, near 16.4%, serve inpatients after surgery or with complications, a shorter episode. Guidelines now look past the hospital stay. At the policy level, the AWMF oncology nutrition guideline aims to improve care for cancer patients beyond sector boundaries.[4] Care across sectors brings home nutrition into the plan, so home care will stay ahead as treatment moves further into outpatient clinics.

• Patients in active treatment, carers and survivors managing weight make up most home-care buyers.
• German guidance is set for years. The AWMF oncology nutrition guideline published in February 2026 is valid until January 2031.[4] A five-year validity period gives suppliers a stable reference for German hospital tenders.

Why does self-pay online buying lead breast cancer nutrition product sales by access route?

Self-pay online buying is forecast to lead access route sales with 38.4% share in 2026, ahead of self-pay pharmacy and retail at about 29.7% and prescribed and reimbursed supply at an estimated 21.5%.

Table 8: Access Route Share for the Breast Cancer Nutrition Product Market (percentage share), 2026

Access Route	Estimated Share (2026)
Self-Pay Online	38.4%
Self-Pay Pharmacy and Retail	29.7%
Prescribed and Reimbursed	21.5%
Cancer Center Supply	10.4%
Total	100.0%

Self-pay online buying is forecast to lead access routes in 2026 at 38.4%, as patients reorder a tolerated flavour by subscription without a trip to the store. Self-pay pharmacy and retail, about 29.7%, serves first purchases and urgent refills, and the Kate Farms shake now reaches drugstore shelves through CVS.[1] Drugstore reach lets a first purchase happen on the way home from an infusion visit. Prescribed and reimbursed supply, near 21.5%, needs a clinician request and payer rules, which slows each order. Lastly, samples and starter packs handed out on infusion days form cancer center supply, an estimated 10.4%. Growth of the medical nutrition market, which covers all diseases, reflects the same prescribed demand. Through 2036, online buying will keep the lead, and reimbursed supply will grow as national guidelines add nutrition to cancer care.

• Brand websites, subscription services and large online pharmacies carry most online orders.
• Coverage is widening for plant-based shakes. Kate Farms products are eligible for coverage through Medicare, Medicaid, private insurance and WIC in 35 states.[1] Insured supply cuts the cost barrier for patients on long treatment courses.

What are the drivers, restraints, and opportunities in the breast cancer nutrition product market?

Treatment side effects that cut appetite keep demand for breast cancer nutrition products rising. Taste fatigue and unclear supplement claims limit repeat buying, and products designed for each treatment phase open new sales.

• Driver: Chemotherapy and radiotherapy reduce appetite and change taste, and oncology teams turn that risk into advice on protein and energy drinks.
• Restraint: Patients tire of one flavour over long treatment courses, and care teams ask patients to check any supplement against current cancer drugs.
• Opportunity: Products designed for each phase, from chemotherapy drinks to survivorship protein, keep patients buying across years of care.

Treatment Side Effects Bring Nutrition into Care Plans

A growing number of patients in active treatment is raising sales of breast cancer nutrition products. For example, new breast cancer cases among US women reached 279,731 in 2022, according to CDC.[2] Every new diagnosis brings a period of appetite loss during treatment. At the same time, the German oncology nutrition guideline aims to counter malnutrition and the serious consequences for prognosis and quality of life across the course of disease.[4] In turn, each new patient screened for nutrition risk adds a likely buyer.

Taste Fatigue and Claim Limits Hold Back Repeat Buying

Producers of cancer nutrition products face patients who stop after a few weeks of one flavour. By one count, Nutricia said about 1 in 5 patients stop a medical nutrition prescription due to flavour fatigue.[8] Drop-outs at that rate make flavour rotation a sales tool. Meanwhile, brands keep labels to nutrition needs and avoid treatment claims. Together, flavour range and careful labelling will decide repeat sales.

Phase-Matched Ranges Open New Sales

Adoption potential of breast cancer nutrition products is highest across the long survivorship period. For instance, England's National Cancer Plan aims for 75% of people diagnosed with cancer to survive five years or more by 2035.[5] More five-year survivors mean more years of protein buying after treatment. In FMI's estimate, endocrine therapy and survivorship together make up 30.8% of 2026 treatment phase sales. Consequently, brands with protein products for weight and muscle in survivorship will gain those longer buying periods.

Which country CAGRs are profiled in the breast cancer nutrition product market?

Table 9: Country CAGR Comparison for the Breast Cancer Nutrition Product Market (CAGR percentage), 2026 to 2036

Country	CAGR (2026 to 2036)
South Korea	9.9%
United States	9.3%
United Kingdom	9%
France	8.9%
Germany	8.7%
Japan	7.5%

How do country-level CAGRs compare in the breast cancer nutrition product market?

Korea has a large and relatively young breast cancer survivor group. Korean registry data released in January 2026 counted 354,699 people living after a breast cancer diagnosis.[3] FMI expects the quickest country gains in South Korea, at 9.9%, ahead of the 9.6% global CAGR, on that growing survivor base. Below South Korea, the United States, at 9.3%, has the largest patient pool and wide retail access. Under the national cancer plan, the United Kingdom is likely to expand 9% a year, with France a tenth lower on prescribed supplements. Close behind, Germany grows at 8.7% under a new oncology nutrition guideline. Japan, at 7.5%, has the slowest country pace, as care routines are long settled.

• Korean survivors are many and often of working age, so protein buying runs for years after treatment, and brands with survivorship ranges in Korean pharmacies and online stores gain most.
• Walmart and CVS listings have put medical shakes on mass US shelves, turning many first purchases into self-pay buys. Brands with coverage eligibility still capture patients who prefer insured supply.
• A 75% five-year survival target for 2035 adds patients to long follow-up care in England. NHS dietitians steer supplement choice, so suppliers need prescribable products more than retail reach.
• French patients receive most medical nutrition on prescription through hospital pharmacies and community prescribers, which narrows the self-pay shelf and leaves volume with prescribed suppliers.
• The 2026 AWMF guideline asks German cancer care to counter undernutrition and build quality indicators. As certification adds nutrition checks, suppliers with guideline-ready products gain hospital listings.
• Hospital nutrition teams in Japan have long-settled routines, leaving home use as the main source of new volume. Compact drinks that fit outpatient schedules hold the clearest opening.

Full report country CAGRs cover: six national rates, with South Korea alone over the 9.6% global figure, the other five below in steps down to Japan, and all remaining standard countries by region.

Country-wise Analysis

South Korea Breast Cancer Nutrition Product Market Outlook (2026 to 2036)

South Korea is expected to be the fastest-growing country, at a 9.9% CAGR, as a long survivorship period keeps patients buying. On the data side, Dailypharm reported on 20 January 2026 that Korea had 2,732,906 cancer survivors in 2023, 5.3% of the population, and that breast cancer was the most common cancer among women aged 40 to 69.[3] In particular, women of working age stay on treatment and survivorship nutrition for many years.

Key takeaway: Korean demand comes as much from survivors managing weight and muscle as from patients in treatment, which rewards brands with survivorship products.

United States Breast Cancer Nutrition Product Market Outlook (2026 to 2036)

FMI estimates a 9.3% CAGR for the United States, reflecting the largest treated population of the six countries and the widest self-pay shelf. To size that population, CDC data updated on 26 May 2026 show 279,731 new female breast cancer cases in 2022 and USD 29.8 billion of breast cancer medical costs in 2020.[2] A caseload of that size gives brands a large pool of first-time buyers each year. On the access side, Kate Farms products are eligible for Medicare, Medicaid and private insurance coverage, and wide retail placement adds self-pay buying.[1] Coverage and shelf access together let patients choose between insured and self-pay supply.

Key takeaway: US brands compete on two fronts at once, mass retail shelves for self-pay buyers and coverage eligibility for insured patients.

United Kingdom Breast Cancer Nutrition Product Market Outlook (2026 to 2036)

British demand is forecast to rise 9% a year as more women enter curative treatment. Published on 4 February 2026, the National Cancer Plan for England targets 75% five-year survival and three in four cancers diagnosed at stage 1 or 2 by 2035.[5] Earlier diagnosis puts more patients on curative pathways that include nutrition advice, and NHS dietitians steer supplement choice during treatment.

Key takeaway: British growth runs through NHS prescribing, as earlier diagnosis and longer survival add patients to dietitian-led care.

France Breast Cancer Nutrition Product Market Outlook (2026 to 2036)

French sales are projected to rise 8.9% a year, with prescribed medical nutrition carrying most demand. On the product side, Nutricia said the new plant-based medical nutrition products, including Fortimel PlantBased Protein for malnutrition due to a medical condition or disease, reached over 10 markets in six months, France among them.[8] Plant-based options give French prescribers an alternative for patients who reject dairy drinks. In practice, hospital pharmacies and community prescribers supply most medical nutrition there, and the self-pay shelf is narrower.

Key takeaway: French volume stays with prescribed medical nutrition, so suppliers gain through hospital pharmacy listings more than through retail.

Germany Breast Cancer Nutrition Product Market Outlook (2026 to 2036)

FMI's forecast for Germany is an 8.7% CAGR, with new guidance formalising nutrition care in oncology. On policy, the AWMF published the guideline Klinische Ernährung in der Onkologie on 19 February 2026, aiming to improve nutrition care across the disease course and develop quality indicators for certification.[4] Over time, certified breast cancer centers will add nutrition checks as those indicators arrive.

Key takeaway: German demand will rise as certified cancer centres adopt the 2026 guideline, giving suppliers a clear standard to meet in tenders.

Japan Breast Cancer Nutrition Product Market Outlook (2026 to 2036)

Japanese demand is likely to expand 7.5% a year in FMI's estimate, 2.1 points under the 9.6% global CAGR, as care routines are long settled. Meanwhile, the National Cancer Center Japan updated national cancer incidence data through 2023 on 3 April 2026.[9] Updated incidence figures guide hospital planning for oncology nutrition supply. Hospital nutrition teams are long established, so growth comes from home use of compact drinks.

Key takeaway: Japanese growth comes from home use of compact drinks between outpatient visits, with hospital supply already mature.

Who are the notable companies in the breast cancer nutrition product market?

Abbott, Danone Nutricia, Nestlé Health Science, Fresenius Kabi, Hormel Health Labs and Medtrition are the profiled companies.

In FMI's view, the market's leading companies include global medical nutrition groups and makers of cancer-oriented meals and protein modules. At the top end, Nestlé Health Science reported 3.2% organic growth and CHF 6,551 million of sales for 2025.[7] Scale of that size supports oncology ranges across many countries. On the deal front, Danone Nutricia added Kate Farms in July 2025, bringing plant-based shakes into the group.[6] Plant-based shakes give Danone a product suited to patients with taste change. Growth is uneven across the large groups, however. Abbott reported adult nutrition sales of USD 1,119 million for the June 2026 quarter, down 4% on a comparable basis.[10] Softer adult nutrition sales push Abbott to defend clinic listings, which strengthens the hand of buyers in price talks. Abbott, Fresenius Kabi, Hormel Health Labs and Medtrition complete the group.

• Multinational clinical nutrition suppliers: Abbott, Danone Nutricia, Nestlé Health Science and Fresenius Kabi.
• Oncology meal makers: Hormel Health Labs.
• Protein module makers: Medtrition.

Competitive Benchmarking: Breast Cancer Nutrition Product Market

Table 10: Competitive Benchmarking for the Breast Cancer Nutrition Product Market (qualitative ratings), 2026

Company	High-Protein Drinks	Retail Access	Prescribed Supply	Recent Activity
Danone Nutricia	High	High	High	High
Nestlé Health Science	High	High	Medium	High
Abbott	High	High	Medium	Medium
Fresenius Kabi	High	Low	High	Low
Hormel Health Labs	Medium	Low	Medium	Low

The table compares the companies on high-protein drinks, retail access, prescribed supply and recent activity.

Key Developments in the Breast Cancer Nutrition Product Market

• Kate Farms said on 28 July 2026 that the High Protein Nutrition Shake would reach over 6,800 Walmart and CVS stores by August 2026, moving medical shakes onto mass retail shelves.[1]
• CDC refreshed breast cancer case and cost data on 26 May 2026, listing 279,731 new female cases for 2022, a reminder of the size of the treated pool.[2]
• In a 3 April 2026 update, the National Cancer Center Japan extended national cancer incidence data through 2023, which supports hospital supply planning.[9]
• On 19 February 2026, the AWMF published the German guideline on clinical nutrition in oncology, pointing cancer centres toward nutrition quality indicators.[4]
• England published a National Cancer Plan with a 75% five-year survival ambition for 2035 on 4 February 2026; for suppliers this means a longer survivorship market.[5]
• On 20 January 2026, Korean registry figures showed 2,732,906 cancer survivors for 2023, a base that keeps survivorship demand growing.[3]

Key Players in the Breast Cancer Nutrition Product Market

Multinational Clinical Nutrition Suppliers

• Abbott
• Danone Nutricia
• Nestlé Health Science
• Fresenius Kabi

Oncology Meal Makers

• Hormel Health Labs

Protein Module Makers

• Medtrition

Breast Cancer Nutrition Product Market - Report Scope

Table 11: Report Scope for the Breast Cancer Nutrition Product Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Product type; treatment phase; product form; care setting; access route; region
Quantitative units	USD million
Market definition	Oral nutrition products bought for people in treatment for breast cancer or in survivorship, covering high-protein oral nutritional supplements, symptom-adapted supplements, fortified meals and snacks and protein modules, supplied through online and retail self-pay, prescription and reimbursement or cancer centers. Tube feeds, parenteral nutrition, cancer drugs, general vitamins and everyday foods are excluded.
Regions covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries covered	United States; Canada; Brazil; Mexico; Argentina; Chile; Germany; France; United Kingdom; Italy; Spain; Benelux; Nordics; Poland; Czech Republic; Romania; Hungary; China; Japan; South Korea; India; ASEAN; Australia and New Zealand; GCC Countries; South Africa; Türkiye; Israel
Key companies profiled	Abbott, Danone Nutricia, Nestlé Health Science, Fresenius Kabi, Hormel Health Labs, Medtrition
Forecast period	2026 to 2036

Breast Cancer Nutrition Product Market - Research Methodology

Table 12: Research Methodology for the Breast Cancer Nutrition Product Market (research methods and approach), 2026 edition

Method	Approach
Data Sources	Cancer registries, public health agencies, clinical guidelines and nutrition company releases.
Desk Research	Desk research covers breast cancer incidence and survival, oncology nutrition guidance, retail and coverage access and supplier moves.
Market Sizing and Forecasting	Sizing starts from the 2026 base of USD 416.9 million and the 9.6% CAGR for 2026 to 2036.
Data Validation	Figures are cross-checked across company, industry and government sources.

Breast Cancer Nutrition Product Market by Segments

Breast Cancer Nutrition Product Market segmented by Product Type:

• High-Protein ONS
• Symptom-Adapted Supplements
• Fortified Meals and Snacks
• Protein Modules
• Others

Breast Cancer Nutrition Product Market segmented by Treatment Phase:

• Chemotherapy and Targeted Therapy
• Surgery and Radiotherapy Recovery
• Endocrine Therapy
• Survivorship

Breast Cancer Nutrition Product Market segmented by Product Form:

• Ready-to-Drink
• Powder
• Puddings and Semi-Solids
• Others

Breast Cancer Nutrition Product Market segmented by Care Setting:

• Home Care
• Cancer Centers
• Hospital Oncology Wards

Breast Cancer Nutrition Product Market segmented by Access Route:

• Self-Pay Online
• Self-Pay Pharmacy and Retail
• Prescribed and Reimbursed
• Cancer Center Supply

Breast Cancer Nutrition Product Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] Kate Farms. (2026, July 28). Kate Farms Expands High Protein Nutrition Shake Into Walmart and CVS as Retail Distribution Grows Sevenfold. https://katefarms.com/news-and-press/press-releases/kate-farms-expands-high-protein-nutrition-shake-into-walmart-and-cvs/
• [2] Centers for Disease Control and Prevention. (2026, May 26). Health and Economic Benefits of Breast Cancer Interventions. https://www.cdc.gov/nccdphp/priorities/breast-cancer.html
• [3] Dailypharm. (2026, January 20). 2.73 million cancer patients, 7 in 10 survive five years or more. https://www.dailypharm.com/user/news/334973
• [4] Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. (2026, February 19). Klinische Ernährung in der Onkologie. https://www.awmf.org/aktuelles/awmf-aktuell/klinische-ernaehrung-in-der-onkologie
• [5] Cancer Research UK. (2026, February 4). A turning point for cancer? Breaking down the National Cancer Plan for England. https://news.cancerresearchuk.org/2026/02/04/breaking-down-the-national-cancer-plan-for-england/
• [6] Danone. (2025, July 1). Danone completes the acquisition of Kate Farms, enhancing its U.S. specialized nutrition offerings. https://www.danone.com/newsroom/press-releases/kate-farms-acquisition.html
• [7] Nestlé S.A. (2026, February 19). Full-year results 2025. https://www.nestle.com/media/pressreleases/allpressreleases/full-year-results-2025
• [8] Nutricia. (2025, October 1). Nutricia's new savory plant-based medical nutrition proven to improve patient adherence. https://www.nutricia.com/latest-news/Fortimel-PlantBased-Protein
• [9] National Cancer Center Japan. (2026, April 3). Cancer Statistics in Japan: Table Download. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html
• [10] Abbott. (2026, July 16). Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance. https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

This bibliography is provided for reader reference. The full report contains the complete reference list and detailed citations.

This Report Answers

• How big is the breast cancer nutrition product market during 2026?
• What market size is projected by 2036?
• Which product type holds notable share?
• Which treatment phase holds notable share?
• Which countries have notable growth?
• Which companies are notable in the market?